SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2020 / The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action litigation on behalf of investors who purchased or otherwise acquired the securities of World Wrestling Entertainment, Inc. ("WWE" or the "Company") (NYSE: WWE) between February 7, 2019 and February 5, 2020, inclusive (the "Class Period").

If you purchased or otherwise acquired the securities of WWE during the Class Period, you may move the Court for appointment as lead plaintiff by no later than May 5, 2020. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

WWE investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

WWE, headquartered in Stamford, Connecticut, is a leading provider of wrestling entertainment. Prior to the Class Period, WWE entered into strategic relationships with the Kingdom of Saudi Arabia, including a multi-year television distributions rights agreement with a Saudi-controlled broadcaster, OSN, and a partnership to host live wrestling events in the country. The strategic relationships were important to WWE's growth prospects and financial success as the Company experienced a declining fan base and deteriorating market in the U.S. WWE, however, faced significant public criticism for pursuing business with the Saudis in light of the country's history of human rights abuses and autocratic policies of its ruling royal family. Unbeknownst to investors, a series of negative developments, including the October 2018 murder of journalist Jamal Khashoggi widely believed to have been directed by the Saudi government, created tensions between the government and WWE that jeopardized the success of their business relationship.

On April 25, 2019, the Company disclosed disappointing financial results for the first quarter of 2019 and weak guidance which analysts believed were related potential issues in the Company's dealings with the Saudis. On this news, the price of WWE Class A common stock fell $13.12 per share, or approximately 13%, to close at $85.38 per share on April 25, 2019, on unusually high trading volume.

On October 31, 2019, WWE announced disappointing financial results for the third quarter of 2019 and that the media rights deal with the Saudis had been indefinitely delayed. In addition, the Saudi government reportedly had withheld tens of millions of dollars in payments owed to WWE. As the dispute escalated, WWE decided to cut a broadcasting feed of a live event held in Saudi Arabia, to which the Saudi government responded by temporarily refusing to allow several WWE wrestlers to leave the country. On this news, the price of WWE stock declined $10.40 per share, or approximately 15%, to close at $56.04 per share on October 31, 2019, on unusually high trading volume.

Then on January 30, 2020, in a startling turn of events, WWE announced that its co-presidents unexpectedly left the Company. On this news, the price of WWE stock declined $13.42 per share, or nearly 22%, to close at $48.88 per share on January 31, 2020, on elevated trading volume.

Shortly thereafter, on February 6, 2020, WWE announced disappointing financial results for the fourth quarter of 2019 and weak guidance due to the Company's failure to secure a favorable broadcasting deal with the Saudis and revealed that the prospective media rights agreement with the Saudis had been excluded from WWE's guidance. On this news, the price of WWE stock declined another $4.50 per share, or 9%, to close at $44.50 per share on February 6, 2020, on unusually high trading volume.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation's top plaintiffs' law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms "representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity." Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm's "laser focus" and noting that our firm routinely finds itself "facing off against some of the largest and strongest defense law firms in the world." Benchmark Litigation has named Lieff Cabraser one of the "Top 10 Plaintiffs' Firms in America."

For more information about Lieff Cabraser and the firm's representation of investors, please visit https://www.lieffcabraser.com/.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source/Contact for Media Inquiries Only

Sharon M. Lee
Lieff Cabraser Heimann & Bernstein, LLP
Telephone: 1-800-541-7358

SOURCE: Lieff Cabraser Heimann & Bernstein, LLP

ReleaseID: 582762

-Company continues to advance preclinical development of its XCART™ CAR T therapy platform –
– Expands XCART resources by adding expertise in cell therapy translational science and CMC –
– Cash on hand expected to fund operations through mid-2021 –

FRAMINGHAM, MA / ACCESSWIRE / March 27, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the year ended December 31, 2019 and provided a corporate update.

Jeffrey Eisenberg, Chief Executive Officer of Xenetic, stated, "2019 proved to be a pivotal year for Xenetic with our completion of the acquisition of XCART, a differentiated CAR T platform technology that we believe has the potential to address a significant unmet need in B-cell non-Hodgkin lymphoma. Moving forward we believe 2020 will be an important year for the Company as we plan to continue driving the development of XCART. To that end, we have made encouraging progress with additions to our team and are advancing towards securing an academic collaboration. We believe this pathway will provide many advantages, including access to manufacturing suites, established CMC and regulatory infrastructure and cost and risk mitigation."

"In the fourth quarter of last year, we received our first royalty payment under our agreement with Takeda involving our proprietary PolyXen® technology in the field of coagulation disorders. While the recognized payment was modest, it is what we expected given the early stages of this product launch. Importantly, the commencement of royalties reaffirms the value of our PolyXen intellectual property and the opportunity to leverage it to prolong a drug's circulating half-life and potentially improve other pharmacological properties. Further, in these unprecedented times, we are reviewing our portfolio of intellectual property assets to see if we can contribute in any way to the global effort to address the current health threat of COVID-19," continued Mr. Eisenberg. "As we advance into the rest of 2020, despite the current climate of financial uncertainty, we are moving our operation and development efforts forward with a strong cash balance which we believe provides us with a cash runway through mid-2021."

XCART Platform Technology Overview: Significantly differentiated, proprietary CAR T therapy designed to develop cell-based therapeutics for the treatment of multiple tumor types of B-cell Non-Hodgkin lymphomas, an area of significant unmet need, with the potential to address an initial global market opportunity of over $5 billion annually.[1] Xenetic believes XCART has the potential to transform CAR T therapy.

The Company has recently bolstered its cell therapy manufacturing and CMC expertise and capabilities with the appointments of Greg MacMichael, Ph.D. and Maksim Mamonkin, Ph.D., to its Scientific Advisory Board. Both Dr. MacMichael and Dr. Mamonkin are actively engaged with the Company to advance the development of the XCART technology platform.

Expected 2020 Milestones

INTERACT meeting with the United States Food and Drug Administration ("FDA")
Enter into an academic site collaboration
Advance IND-enabling studies
Explore opportunities for Orphan Drug designation

PolyXen Platform Technology: Patent-protected platform technology designed for protein or peptide therapeutics, enabling next-generation biological drugs by prolonging a drug's circulating half-life and potentially improving other pharmacological properties.

Program Highlights:

Exclusive License Agreement with Takeda Pharmaceuticals Co. Ltd. ("Takeda") in the field of coagulation disorders. Takeda currently has one active development program underway utilizing the PolyXen platform technology.
The Company received $17,000 in royalty revenue during the fourth quarter of 2019 representing its first payment under the Company's license agreement with Takeda. This payment and expected future payments relate to a sublicense of Xenetic's PolyXen intellectual property, entered into by Takeda with a third party in 2017. The Company expects this quarterly royalty payment to increase as the relevant product launch continues to be rolled out by the sublicensee.

Mr. Eisenberg concluded, "We are closely monitoring the evolving COVID-19 situation. While the situation is very fluid, to date we have not experienced any significant impact or delays on our projected timelines. The safety and wellness of our employees, partners and the community are of the upmost importance to us and we have implemented risk mitigation strategies to ensure the least amount of disruption to our operations as possible."

Summary of Financial Results for Fiscal Year 2019

Net cash used in operating activities for the year was $6.4 million. During 2019, our working capital increased by $10.1 million primarily due to our March 2019 registered direct offering and our July 2019 public offering that resulted in $16.1 million in combined net proceeds. This increase in working capital was partially offset by the Company's reported net loss for the year ended December 31, 2019. The Company ended the year with approximately $­10.4 million of cash.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.

For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including, but not limited to, statements regarding the Company's belief that 2020 will be an important year for the Company as it plans to continue driving the development of XCART, statements regarding advancing towards and the timing of securing an academic collaboration for the development of XCART, including the Company's belief that this pathway will provide many advantages, including access to manufacturing suites, established CMC and regulatory infrastructure and cost and risk mitigation, statements regarding the Company's belief that moving the Company's operation and development efforts forward with a strong cash balance will provide Xenetic with a cash runway through mid-2021, statements related to the Company's belief that XCART has the potential to transform CAR T therapy, all statements under the caption "Expected 2020 Milestones" including expected timing of completing INTERACT meetings with the FDA, entering into academic site collaborations, advancing IND-enabling studies and exploring opportunities for Orphan Drug designation, statements regarding the receipt of future quarterly royalty payments related to a sublicense of Xenetic's PolyXen intellectual property entered into by Takeda with a third party in 2017, including expectations that this quarterly royalty payment will increase as the relevant product launch continues to be rolled out by the sublicensee, the Company's plans to initially apply the XCART technology to advance cell-based therapeutics by targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas, the Company's expectations that XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications, and the Company's expectations that XCART has the potential to address a significant unmet need in B-cell Hodgkin lymphoma. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from the acquisition of XCART; (2) uncertainty of the expected financial performance of the Company following completion of the acquisition of XCART; (3) failure to realize the anticipated potential of the XCART technology; (4) the ability of the Company to implement its business strategy; and (5) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, periodic current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com

[1] Market Reports World GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET – SEGMENTED BY TYPE OF TREATMENT – GROWTH, TRENDS AND FORECASTS (2018 – 2023); BioPharm Insight Surveillance, Epidemiology, and End Results (SEER) 9 registries, National Cancer Institute, 2017

SOURCE: Xenetic Biosciences, Inc.

ReleaseID: 582778

NORTH MIAMI BEACH, FL / ACCESSWIRE / March 27, 2020 / Hemp Naturals Inc. (OTC PINK:HPMM) has proudly announced that it has recently launched an all-new line of Premium CBD products in the market. These new products will now be available at Valero, located at 201 NE 183rd St Miami Florida 33179 and Oriental Spa, located at 1991 NE 163rd St. North Miami Beach, FL 33166 this week onwards and they're a great addition to the growing availability of our CBD Gummies.

CBD is basically a superfood that when taken regularly, provides a broad host of amazing physiological benefits. Also, each product is handcrafted and proudly made in the USA. "Our hand-crafted CBD Gummies are FDA audited and are produced in a GMP compliant facility with pure Colorado hemp CBD." The spokesperson added. Each product manufactured by the company is not only all-natural but also organic, gluten free and non-GMO. Furthermore, precisely 25mg of hemp extract is used per gummy and these products are also third-party tested and are certified for being free of any kind of THC, chemicals and pesticides.

This is a very exciting time for CBD companies to begin exploring new ways to improve the lives of those in our communities at Hemp Naturals. We are experiencing the start of a new age in this country, when people's access to an improved quality of life is going to change dramatically through everyday products, and we are blessed and thrilled to help carry Florida into that future.

Cautionary Language Concerning Forward-Looking Statements:

This release contains "forward-looking statements" that include information relating to future events and future financial and operating performance. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential," and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for Hemp Naturals products, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in Hemp Naturals filings with the United States Securities and Exchange Commission. Examples of such forward-looking statements in this release include statements regarding future sales, costs and market acceptance of products as well as regulatory actions at the State or Federal level. For a more detailed description of the risk factors and uncertainties affecting Hemp Naturals please refer to the Company's Securities and Exchange Commission filings, which are available at www.sec.gov. Hemp Naturals undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Hempofnaturals@gmail.com
Hempofnaturals.com
Levi Jacobson

SOURCE: Hemp Naturals Inc.

ReleaseID: 582695

CORAL GABLES, FL / ACCESSWIRE / March 27, 2020 / The top website for all things gold stocks, GoldStocks.com just released a new & exclusive article titled: Is Gold A Ticking Time Bomb Right Now? The team at GoldStocks.com talks about 3 gold stocks to watch before the weekend.

Within this article, GoldStocks.com discusses how: "Right now there could be a hidden market for gold. One that suggests pent up demand has driven gold prices higher even compared to Wall Street figures. In an article on MarketWatch, Josh Strauss, partner at money manager Pekin Hardy Strauss in Chicago gave his take:

"There's no gold. There's roughly a 10% premium to purchase physical gold for delivery. Usually, it's like 2%. I can buy a one-ounce American Eagle for $1,800; $1,800!"

Strauss's comments raise some questions as to the real market value of gold. Fundamentally it makes sense as the Federal Reserve and U.S. government are shelling out fresh greenbacks to support the economy. So does this mean gold could be a ticking timebomb for a pending bull market? Heading into the end of March, here's a list of gold stocks to watch including Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX)."(click here for the full article)

Read the article from GoldStocks.com titled: Is Gold A Ticking Time Bomb Right Now? <<< Click Here

Gold Stocks (GoldStocks.com)

GoldStocks.com is the best place to find the top gold stocks to buy, a full list of gold stocks and mining stock news, articles & information. Mining stocks and Gold Stocks are off to a very strong start in 2020 and are expected to continue their bullish run. Subscribe, to our Free Gold Stocks Newsletter and stay updated on the top gold stocks picks, exclusive articles, gold stock alerts and mining company news.

Contact:

Name: Adam Lawrence
Email: news@goldstocks.com
Phone: (305) 390-2368

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MIDAM VENTURES LLC, which owns www.GoldStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Please Read Our Full Disclosure Located Here: https://goldstocks.com/disclaimer/

SOURCE: GoldStocks.com

ReleaseID: 582828

TORONTO, ON / ACCESSWIRE / March 27, 2020 / Mongolia Growth Group Ltd. (TSXV:YAK)(OTC:MNGGF) ("MGG") or ("the Company") a commercial real estate investment company participating in the Mongolian economy announces that it has donated 20,000 protective masks to the National Center for Communicable Diseases and to the National Center for Maternal and Child Health.

As a long-term investor in Mongolia, MGG is highly concerned about the spread of COVID-19 within Mongolia and intends to do its part to make protective materials available to national organizations that are in need.

MGG recently published a video for Mongolian social media. Please visit the following link https://youtu.be/GbgO6y_rtu0 to see that video with English language subtitles.

MGG intends to closely monitor the ongoing virus situation for the health and safety of all employees.

For further information on the Corporation, please visit www.mongoliagrowthgroup.com

or contact:

Ms. Genevieve Walkden, Corporate Secretary
(877) 644-1186
gwalkden@MongoliaGrowthGroup.com

Mongolia Growth Group Ltd. is a publicly traded and leading property investment and development company in Ulaanbaatar, Mongolia. Mongolia Growth Group Ltd. owns an extensive property portfolio in diversified segments of the property market, with an emphasis on institutional-grade commercial assets.

Forward-looking Information and Statements

This press release contains certain statements or disclosures relating to MGG that are based on the expectations of its management as well as assumptions made by and information currently available to MGG which may constitute forward-looking statements or information ("forward-looking statements") under applicable securities laws. All such statements and disclosures, other than those of historical fact, which address activities, events, outcomes, results or developments that MGG anticipates or expects may, or will occur in the future (in whole or in part) should be considered forward-looking statements. In some cases, forward-looking statements can be identified by terms such as "forecast", "future", "may", "will", "expect", "anticipate", "believe", "potential", "enable", "plan", "continue", "contemplate", "pro-forma", or other comparable terminology.

In particular, forward-looking statements in this press release include, but are not limited to, statements concerning MGG's upcoming annual meeting of shareholders and the timing thereof, the approval of the Rights Plan, the operation of the Rights Plan in the event of certain circumstances, and the amendments to the General By-Law.

Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by MGG as of the date of such statements, are inherently subject to business, economic and competitive uncertainties and contingencies. The assumptions of MGG used for this news release may prove to be incorrect. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks which could cause actual results to vary and in some instances to differ materially from those anticipated by MGG and described in the forward-looking statements contained in this press release.

Although MGG believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance. MGG's actual results may differ materially from those expressed or implied in forward-looking statements and readers should no place undue importance or reliance on the forward looking-statements. Statements including forward looking statements are made as of the date they are given and, except as required by applicable securities laws, MGG disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Mongolia Growth Group Ltd.

ReleaseID: 582829

CORAL GABLES, FL / ACCESSWIRE / March 27, 2020 / The top website for all things penny stocks, PennyStocks.com just released a new, exclusive & informative article titled: Best Penny Stocks To Watch Before The Weekend? The team at PennyStocks.com discusses several penny stocks to watch before the weekend and are all making bigger moves on Friday morning.

Within this article, PennyStocks.com states how: "The market has seen historic moves and it's still not over yet. The government and Federal Reserve are flooding money to protect against the COVID-19 potential fallout. Aside from that, even historically high jobless claims couldn't slow things down. But while broader markets are seeing increased volatility, penny stocks are on fire."

The top site for all things penny stocks continues: "We've seen some of the most consecutive days of multiple 100%+ breakout stocks. While several have seen simple, 1-day moves, others have gone on to rally for days. So what's this mean? In my opinion, it could mean big things for low priced stocks. Heading into the end of the week, where will the attention be next? Here's a quick list of penny stocks to watch before the weekend including BIO-key International, Inc. (BKYI)."

Read the article from PennyStocks.com titled: Best Penny Stocks To Watch Before The Weekend?<<

Penny Stocks (PennyStocks.com)

PennyStocks.com is the best place to find the top penny stocks to buy, a full list of penny stocks and small cap stock news, articles & information. Penny stocks are off to a very strong start in 2020 and are expected to continue their bullish run. Subscribe, to our Free Penny Stocks Newsletter and stay updated on the top penny stock picks, exclusive articles & small cap stock alerts.

Contact:

Name: Adam Lawrence
Email: news@pennystocks.com
Phone: (305) 204-3247

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MIDAM VENTURES LLC, which owns www.PennyStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Please Read Our Full Disclosure Located Here: https://pennystocks.com/disclaimer/

SOURCE: PennyStocks.com

ReleaseID: 582827

Dr. Braunstein is recognized worldwide in Psychedelic Psychiatry, which entails treating psychiatric disorders with psychedelics

MIAMI, FL / ACCESSWIRE / March 27, 2020 / Ehave, Inc., (OTC PINK:EHVVF) (the "Company"), announced today that Dr. Mark Braunstein, DO, ABPN has been appointed to its Medical Advisory Board as its Chief Psychedelic Officer. Dr. Braunstein will join other members of the Medical Advisory Board evaluating various technologies, acquisitions, investments, joint ventures, and all other business related to psychedelics.

Dr. Braunstein is a renowned expert on psychedelic therapy and addiction. As a pioneer in psychedelic medicine research, he specializes in the treatment of ADHD, depression, anxiety, bipolar disorder, substance abuse, oppositional defiance, personality disorders, and treatment resistance. He has maintained a private psychiatric practice in Durango, Colorado for the past 17 years and works with students and families at the world-renowned Open Sky Wilderness Therapy facility.

To view the full release with downloadable visuals and more, click here.

Key Takeaways:

Dr. Mark Braunstein, DO, ABPN has been appointed its Medical Advisory Board as its Chief Psychedelic Officer. Dr. Braunstein will join other members of the Medical Advisory Board evaluating various technologies, acquisitions, investments, joint ventures, and all other business related to psychedelics.
Dr. Braunstein is a renowned expert on psychedelic therapy and addiction. As a pioneer in psychedelic medicine research, he specializes in the treatment of ADHD, depression, anxiety, bipolar disorder, substance abuse, oppositional defiance, personality disorders, and treatment resistance.
Ehave is developing software-based solutions for the digital assessment and remediation of the most common mental health disorders faced by children and adolescents.

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. For more information visit: www.ehave.com.

Forward-Looking Statement Disclaimer

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.

CONTACT:
Gabe Rodriguez
ir@ehave.com
(623) 261-9046
Investor

SOURCE: Ehave

ReleaseID: 582824

Partnership with 3D Manufacturing Software Provider Expands Industry Footprint and Worldwide Distribution Channels

SANTA FE, NM / ACCESSWIRE / March 27, 2020 / Sigma Labs, Inc. (NASDAQ:SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, has selected Excel3D Advanced Technologies, a provider of 3D manufacturing software as its preferred value-added reseller for sales of Sigma Labs products in India. This agreement expands Sigma Labs global footprint into the world's fifth-largest manufacturing economy and in conjunction with the Indian government's initiative of ‘Make in India', the nation's vision is to make the country a global manufacturing hub.

The partnership with Excel3D is an evolution of Sigma Labs' multi-channel go-to-market strategy to address the worldwide demand for its products. Sigma Labs provides service to end-users as well as contract manufacturers in North America and Europe through direct sales and support teams, to service other global markets that require local sales and support infrastructure, in countries such as India and Japan, Sigma Labs is building a network of resellers to enable the company to most efficiently scale its global footprint in a capital-light manner.

Excel3D will be helping industrial clients in India with support from Sigma Labs, Inc. to implement their novel and unique flagship product PrintRite3D® as the quality assurance system for metal powder bed fusion process of additive manufacturing technology.

"As Sigma embarks on advancing several active sales initiatives in India, establishing a local service footprint is critical to our ability to support our customers and ensure their success," said Mark K. Ruport, Executive Chairman of Sigma Labs. "Excel3D is uniquely qualified to help us expand into the Indian market. They are familiar with our technology and have a singular focus on their customer's success, making this partnership a natural alignment for both companies."

"We are truly honored to work with innovators like Sigma Labs, who are addressing common pain points in commercialization of additive manufacturing technology; such as machine qualification needs from regulatory bodies, process robustness and challenges in part or process qualification which are experienced daily by our additive manufacturing client base," added Sameet Raut, CEO at Excel3D Advanced Technologies. "We look forward to commercializing their product amongst our robust client base in the Indian additive manufacturing sector to promote further growth and instill the confidence in the technology for wide range of applications."

PrintRite3D® is Sigma Labs' patented in-process quality assurance software for the commercial 3D metal printing industry, providing real-time melt pool analytics. The software uniquely leverages thermal signatures to monitor the quality of each product part in the production process, layer by layer and in real-time, allowing operators to correct or stop production of a defective part – resulting in reduced error rates and higher yields. The software is currently being evaluated by tier-1 manufacturing companies and OEM partners worldwide.

About Excel3D Advanced Technologies

Excel3D is dedicated to transfer advanced technologies with relevant know-how in the field of design, materials and processes to manufacture end-use parts; so that it can be implemented for high value and demanding engineering applications. Excel3D will adopt the approach to educate the current and future engineers, promote the adoption of advanced manufacturing technologies to instill confidence in a wide range of industries which will enable the development of products to achieve better efficiency, quality and productivity to serve the end-user. Excel3D will also be committed to develop innovative products for the wide range of applications serving environmental, engineering and social needs as well as upskill the current and future workforce to support growth for advanced technologies.

About Sigma Labs

Sigma Labs, Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D® brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer-aided inspection (CAI) solutions known as PrintRite3D® for 3D advanced manufacturing technologies. Sigma Labs' advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.sigmalabsinc.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K (including but not limited to the discussion under "Risk Factors" therein) filed with the SEC on April 1, 2019, and which may be viewed at www.sec.gov.

Contacts:

Media Contact:

Julia Wakefield
Vice President
Rubenstein Public Relations
212-805-3021
jwakefield@rubensteinpr.com
www.rubensteinpr.com

Investor Contact:

Chris Tyson
Managing Director
MZ Group – MZ North America
949-491-8235
SGLB@mzgroup.us

Company Contact:

Steven Gersten
Sigma Internal IR
investors@sigmalabsinc.com

SOURCE: Sigma Labs, Inc.

ReleaseID: 582749

Not for Distribution to U.S. Newswire Services or For Dissemination in the United States. any Failure to Comply with this Restriction may Constitute a Violation of U.S. Securities Law.

CALGARY, AB / ACCESSWIRE / March 27, 2020 / CANEX Metals Inc. (TSXV:CANX) ("CANEX" or the "Company") announces that it has amended its non brokered private placement originally announced on February 26, 2020, in order to reflect current market conditions.

The revised private placement will consist of up to 5,555,555 shares ("Common Shares") at a price of $0.09 per Common Share for gross proceeds of up to $500,000. The shares will be offered on a non-brokered basis by way of private placement to accredited investors and any securities issued will be subject to a hold period of four months plus one day from the date of closing. This financing is subject to TSX Venture Exchange and regulatory approval. Proceeds of the financing will be used to further explore the Gold Range Property, to evaluate additional exploration opportunities, and for general working capital.

Exploration Update

In February and March the Company conducted mapping and sampling programs at Gold Range in preparation for a final trenching program prior to selecting drill targets. The March program was ended prior to completion to comply with health and travel advisories related to the coronavirus pandemic. The Company intends to continue exploration at Gold Range once travel restrictions are lifted and work can resume in the area.

Results of sampling and mapping completed to date will be released once they are received and interpreted. The Company will utilize the current hiatus in exploration to compile and prioritize exploration targets at Gold Range and evaluate new opportunities.

About the Gold Range Property

The Gold Range Property is located in Northern Arizona within an area that has seen historic lode and placer gold production but limited systematic modern lode gold exploration. Fieldwork by the Company has identified numerous gold exploration targets on the property with grab samples from outcropping quartz veins returning multiple values in the 20 to 40 g/t gold range, and chip sampling returning values of 31.7 g/t gold over 1 metre, 24.3 g/t gold over 1.5 metres, 28.1 g/t gold over 1 metre, 17.2 g/t over 1.1 metres, and 8.47 g/t gold over 5.6 metres. Please visit our website at www.canexmetals.ca for additionnel information.

Dr. Shane Ebert P.Geo., is the Qualified Person for CANEX Metals and has approved the technical disclosure contained in this news release.

"Shane Ebert"

Shane Ebert,
President/Director

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Except for the historical and present factual information contained herein, the matters set forth in this news release, including words such as "expects", "projects", "plans", "anticipates" and similar expressions, are forward-looking information that represents management of CANEX Metals Inc. internal projections, expectations or beliefs concerning, among other things, future operating results and various components thereof or the economic performance of CANEX. The projections, estimates and beliefs contained in such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause CANEX's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, those described in CANEX's filings with the Canadian securities authorities. Accordingly, holders of CANEX shares and potential investors are cautioned that events or circumstances could cause results to differ materially from those predicted. CANEX disclaims any responsibility to update these forward-looking statements.

For Further Information Contact:

Shane Ebert at 1.250.964.2699 or
Jean Pierre Jutras at 1.403.233.2636
Web:  http://www.canexmetals.ca

SOURCE: CANEX Metals Inc.

ReleaseID: 582813

Initial focus will be on helping businesses secure SBA Disaster Loans, with additional value-add services for navigating the impact of the COVID-19 crisis

NEW YORK, NY / ACCESSWIRE / March 27, 2020 / MZ, a global leader in investor relations and corporate communications, today announced the launch of a disaster relief consulting service, MZ Assist, for private and public companies seeking financial assistance from government loan and stimulus programs created in response to the COVID-19 crisis and coronavirus communication programs.

The COVID-19 pandemic has caused a crisis for many businesses, severely impacting the productivity of employees, the purchasing appetite of clients and the availability of key suppliers. As part of the government's economic stimulus efforts to fight the pandemic driven recession, the President today signed a bill that includes $367 billion for a small business disaster assistance loan program. U.S. small business owners are now eligible to apply for this low-interest disaster loan.

MZ's team has significant experience guiding companies through traditional SBA and bank loan transactions and is now offering their expertise to companies seeking to apply for funds through the SBA disaster assistance loan program. Traditionally, governmental SBA loans require further paperwork and documentation than typical business loans to meet SBA qualification standards, a time consuming and resource-intensive activity for companies already dealing with a crisis.

MZ Assist will initially focus on guiding clients from application to deployment of the SBA's Economic Injury Disaster Loans (EIDL) process. MZ services include:

Education on the funding process & expected timeline
Determining eligibility
Preparing the loan application and supporting documents
Providing strategic advice to the deployment of loan proceeds
Assist with tailoring loan programs to company capital structures

The service offers forward-thinking clients the opportunity to engage MZ for ongoing advisory as new state or federal initiatives arise and other resources are offered, as well as COVID-19 investor communications strategies and technology tools for their business.

"Our goal is to lead our clients through this crisis successfully, utilizing our broad set of skills and expertise from securing capital to communicating with investors and shareholders," said Ted Haberfield, President of MZ North America. "We can provide one-time expertise on the SBA program, or help companies interested in a comprehensive advisory and consulting package that will carry your business through this volatile market and beyond. This is a moment for all of us to support one another in the best way that we can. For MZ and our team, we believe this service is the most effective way we as a company can help the clients, partners and friends for whom we care."

To get started go to the following link: https://mzgroup.us/mz-assist/

You can also contact us by email at mzassist@mzgroup.us or by phone at 212-301-7130.

About MZ Group

MZ North America is the US division of MZ Group, a global leader in investor relations and corporate communications. MZ North America was founded in 1996 and provides full-scale Investor Relations to both private and public companies across all industries. MZ North America has a global footprint with offices located in New York, Chicago, San Diego, Aliso Viejo, Austin, Minneapolis, Taipei and São Paulo. For more information, please visit www.mzgroup.us.

CONTACT:

Ted Haberfield
MZ Group | President – MZ North America
Direct: 760-755-2716
thaberfield@mzgroup.us

SOURCE: MZ North America

ReleaseID: 582812